Progress in stem cell technologies is advancing powerful new ways of studying and treating formerly intractable neurological and neuropsychiatric diseases. Several interwoven examples have been discussed at Neuroscience 2024, the annual meeting of the Society for Neuroscience.

Over 40% of the global population lives with some kind of neurological condition, and this number is projected to double by 2050. Due to their regenerative potential, stem cells have emerged as a unique and versatile tool for devising new therapeutic strategies for brain diseases.

Cell replacement therapies for some neurological diseases are in clinical trials and others are at earlier stages of investigation. In addition, research platforms using human stem cells are increasingly used to model diseases and test potential therapeutics.

Speaker discussions

Rita Sattler from the Barrow Neurological Institute discussed modelling and studying synapse dysfunction in dementias and other neurodegenerative diseases with patient-derived stem cells.

Sergiu Pasca from Stanford University School of Medicine discussed using human stem cells to create three-dimensional complex clusters of cultured patient-derived cells called brain organoids and assembloids to better reproduce the complexity of human neuropsychiatric disorders and test potential therapeutics.

Catherine Priest from Neurona Therapeutics discussed the development and clinical trial of a potential off-the-shelf, single-dose cell therapy for epilepsy.

Merit Cudkowicz from Massachusetts General Hospital discussed current stem cell clinical trials in amyotrophic lateral sclerosis (ALS) and the use of models from induced pluripotent stem cells to develop more targeted treatments for ALS.

“These talks illustrate the value of human stem cells in regenerative medicine as well as in modelling diseases to design safe and effective therapies,” said Dr Lee Rubin, Co-director of the Harvard Stem Cell Institute Nervous System Disease Program. “Stem cell-based therapies and model systems hold great promise for neurological and neuropsychiatric diseases that are currently very challenging to treat.”

Megan Thomas, Multimedia Editor, DDW